Sorafenib resistance in hepatocarcinoma: role of hypoxia-inducible factors

Volume: 50, Issue: 10, Pages: 1 - 9
Published: Oct 1, 2018
Abstract
Sorafenib, a multikinase inhibitor with antiproliferative, antiangiogenic, and proapoptotic properties, constitutes the only effective first-line drug approved for the treatment of advanced hepatocellular carcinoma (HCC). Despite its capacity to increase survival in HCC patients, its success is quite low in the long term owing to the development of resistant cells through several mechanisms. Among these mechanisms, the antiangiogenic effects of...
Paper Details
Title
Sorafenib resistance in hepatocarcinoma: role of hypoxia-inducible factors
Published Date
Oct 1, 2018
Volume
50
Issue
10
Pages
1 - 9
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.